차세대 조직 바이오마커 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 유형별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Next Generation Tissue Biomarkers Market Summary

The global next generation tissue biomarkers market size was valued at USD 3.3 billion in 2025 and is projected to grow from USD 3.6 billion in 2026 to USD 6.0 billion by 2033, at a CAGR of 7.5% from 2026 to 2033. North America dominated the market with the largest revenue share of 46.4% in 2025.

Global Next Generation Tissue Biomarkers Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global next generation tissue biomarkers market report based on product, application, technology, type, end use, and region:

• Product Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Reagents & Assays
• Instruments & Platforms
• Software & AI
• Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Genomic Biomarkers
• Proteomic Biomarkers
• Epigenetic Biomarkers
• Transcriptomic Biomarkers
• Metabolomic Biomarkers
• Technology Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Immunohistochemistry
• Next-Generation Sequencing (NGS)
• Mass Spectrometry (MS)-based Proteomics
• Spatial Biology Platforms
• Digital Pathology & AI Analysis
• Others
• Application Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Oncology
• Companion Diagnostics
• Drug Discovery & Development
• Neurology
• Others
• End-use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Hospitals & Reference Labs
• Pharma & Biotech Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. Type
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Application outlook
  • 2.2.4. Type outlook
  • 2.2.5. End Use outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Next Generation Tissue Biomarker Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rise of Precision Medicine and Companion Diagnostics
    • 3.2.1.2. Technological Advancements in Spatial Biology and NGS
    • 3.2.1.3. Expansion of Clinical Utility Across Disease Areas
    • 3.2.1.4. Growth in Digital Pathology and AI-Driven Analysis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Multi-Omic Platforms and Reagents
    • 3.2.2.2. Data Privacy and Infrastructure Barriers in AI Adoption
• 3.3. Next Generation Tissue Biomarker Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Next Generation Tissue Biomarker Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Next Generation Tissue Biomarker Market: Product Movement Analysis
• 4.3. Next Generation Tissue Biomarker Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million/Billion)
• 4.4. Reagents & Assays
  • 4.4.1. Reagents & Assays Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.5. Instruments & Platforms
  • 4.5.1. Instruments & Platforms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.6. Software & AI
  • 4.6.1. Software & AI Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 5. Next Generation Tissue Biomarker Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Next Generation Tissue Biomarkers Market by Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Genomic Biomarkers
  • 5.5.1. Genomic Biomarkers Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 5.6. Proteomic Biomarkers
  • 5.6.1. Proteomic Biomarkers Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 5.7. Proteomic Biomarkers
  • 5.7.1. Proteomic Biomarkers Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 5.8. Epigenetic Biomarkers
  • 5.8.1. Epigenetic Biomarkers Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 5.9. Transcriptomic Biomarkers
  • 5.9.1. Transcriptomic Biomarkers Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 5.10. Metabolomic Biomarkers
  • 5.10.1. Metabolomic Biomarkers Market estimates and forecasts 2021 to 2033 (USD Million/Billion)

Chapter 6. Next Generation Tissue Biomarker Market: Technology Estimates & Trend Analysis

• 6.1. Technology Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Next Generation Tissue Biomarkers Market by Technology Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Immunohistochemistry
  • 6.5.1. Immunohistochemistry Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 6.6. Next-Generation Sequencing (NGS)
  • 6.6.1. Next-Generation Sequencing (NGS) Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 6.7. Mass Spectrometry (MS)-based Proteomics
  • 6.7.1. Mass Spectrometry (MS)-based Proteomics Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 6.8. Spatial Biology Platforms
  • 6.8.1. Spatial Biology Platforms Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 6.9. Digital Pathology & AI Analysis
  • 6.9.1. Digital Pathology & AI Analysis Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 6.10. Others
  • 6.10.1. Others Market estimates and forecasts 2021 to 2033 (USD Million/Billion)

Chapter 7. Next Generation Tissue Biomarker Market: Application Estimates & Trend Analysis

• 7.1. Application Market Share, 2025 & 2033
• 7.2. Segment Dashboard
• 7.3. Next Generation Tissue Biomarkers Market by Application Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Oncology
  • 7.5.1. Oncology Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 7.6. Companion Diagnostics
  • 7.6.1. Companion Diagnostics Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 7.7. Drug Discovery & Development
  • 7.7.1. Drug Discovery & Development Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 7.8. Neurology
  • 7.8.1. Neurology Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 7.9. Others
  • 7.9.1. Others Market estimates and forecasts 2021 to 2033 (USD Million/Billion)

Chapter 8. Next Generation Tissue Biomarker Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2025 & 2033
• 8.2. Segment Dashboard
• 8.3. Next Generation Tissue Biomarkers Market by End Use Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 8.5. Hospitals & Reference Labs
  • 8.5.1. Hospitals & Reference Labs Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 8.6. Pharma & Biotech Companies
  • 8.6.1. Pharma & Biotech Companies Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 8.7. Academic and Research Institutes
  • 8.7.1. Academic and Research Institutes Market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 8.8. Contract Research Organizations (CROs)
  • 8.8.1. Contract Research Organizations (CROs) Market estimates and forecasts 2021 to 2033 (USD Million/Billion)

Chapter 9. Next Generation Tissue Biomarker Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 9.5. North America
  • 9.5.1. North America
  • 9.5.2. U.S.
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/Reimbursement
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.5.3. Canada
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/Reimbursement
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.5.4. Mexico
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/Reimbursement
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 9.6. Europe
  • 9.6.1. Europe
  • 9.6.2. UK
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/Reimbursement
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.6.3. Germany
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/Reimbursement
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.6.4. France
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/Reimbursement
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.6.5. Italy
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/Reimbursement
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.6.6. Spain
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/Reimbursement
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.6.7. Norway
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/Reimbursement
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.6.8. Sweden
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/Reimbursement
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.6.9. Denmark
    • 9.6.9.1. Key country dynamics
    • 9.6.9.2. Regulatory framework/Reimbursement
    • 9.6.9.3. Competitive scenario
    • 9.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 9.7. Asia Pacific
  • 9.7.1. Asia Pacific
  • 9.7.2. Japan
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/Reimbursement
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.7.3. China
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/Reimbursement
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.7.4. India
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/Reimbursement
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.7.5. Australia
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/Reimbursement
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.7.6. South Korea
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/Reimbursement
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.7.7. Thailand
    • 9.7.7.1. Key country dynamics
    • 9.7.7.2. Regulatory framework/Reimbursement
    • 9.7.7.3. Competitive scenario
    • 9.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 9.8. Latin America
  • 9.8.1. Latin America
  • 9.8.2. Brazil
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/Reimbursement
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/Reimbursement
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million/Billion)
• 9.9. MEA
  • 9.9.1. MEA
  • 9.9.2. South Africa
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/Reimbursement
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.9.3. Saudi Arabia
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/Reimbursement
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.9.4. UAE
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/Reimbursement
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million/Billion)
  • 9.9.5. Kuwait
    • 9.9.5.1. Key country dynamics
    • 9.9.5.2. Regulatory framework
    • 9.9.5.3. Competitive scenario
    • 9.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million/Billion)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2025
  • 10.3.4. Roche Diagnostics / Ventana Medical Systems
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Services benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Agilent Technologies / Dako
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Services benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Thermo Fisher Scientific
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Services benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Leica Biosystems (Danaher Corporation)
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Services benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Illumina
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Services benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Qiagen
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Services benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. NeoGenomics
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Services benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. NanoString Technologies
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Services benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Akoya Biosciences
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Services benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Bio-Techne / ACD
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Services benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Guardant Health
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Services benchmarking
    • 10.3.14.4. Strategic initiatives